Mutations at a similar position in ribosomal protein L4 and 23S rRNA have been reported previously in macrolide-resistant pneumococci. This report shows that similar mutations can be found in macrolide-resistant S. pyogenes.
Introduction
Although penicillins are still the first-line treatment for Streptococcus pyogenes (group A streptococcus) pharyngitis, macrolides are often the recommended substitute when these antimicrobials fail or in cases of patient intolerance to these drugs. In addition, short-course therapy with certain macrolides, such as azithromycin, has been reported to be effective for eradicating oropharyngeal S. pyogenes. 1 Although the incidence of resistance to macrolides in S. pyogenes was low in the past, high incidences have now been reported from several countries including Finland, Italy, Korea, Spain and Thailand. [2] [3] [4] [5] [6] Epidemiological surveys have shown that the acquisition of erm(B) and erm(A) genes, encoding ribosomal methylases, and of mef(A) genes, encoding efflux proteins, accounted for resistance in nearly all strains. [5] [6] [7] [8] In this report, we show that ribosomal mutations affecting sites involved directly or indirectly in ribosomal binding of macrolides may also be a cause of resistance to macrolides and related antibiotics in S. pyogenes.
Materials and methods

Bacterial strains
A large number of clinical isolates of S. pyogenes strains resistant to macrolides collected during a multicentre European study were studied for the presence of erm(B) and 9 S. pyogenes strains 237 and 544, isolated in Slovakia and Croatia from the ear of a 1-year-old child suffering from otitis, and from a throat sample from a 20-year-old patient, respectively, did not contain either gene and were studied further. Erythromycin-susceptible clinical isolates of S. pyogenes, UCN5 and 11, were used as controls for PCR and MIC studies.
MIC determination
MICs of azithromycin, clindamycin, dalfopristin, erythromycin, quinupristin, quinupristin-dalfopristin, spiramycin and telithromycin were determined by the agar dilution method with Mueller-Hinton medium supplemented with 5% defibrinated sheep blood. 10 Agar plates were incubated overnight at 37°C in ambient air.
Detection of erythromycin resistance genes
The erythromycin-resistant isolates were screened for the erythromycin resistance genes erm (A) 
Detection of mutations in the ribosomal target of macrolides
Nucleotide sequences of 23S rRNA and L4 and L22 ribosomal proteins in Escherichia coli were obtained from The Institute for Genomic Research website (www.tigr.org) and homologues were detected in S. pyogenes by using BLAST software (www.ncbi.nlm.nih.gov/Microb_blast). 12 Specific oligonucleotide primers were then designed. We amplified a portion of the rrl gene for domain II, from nucleotide 580 to 852 (E. coli numbering) with primers 5′-CGGCGATTAC-GATATGATGC-3′ and 5′-CTCTAATGTCGACGCTA-GCC-3′, and two overlapping fragments of domain V of 23S rRNA (nucleotides 1990-2405 and 2331-2769) with the two pairs of primers 5′-CTGTCTCAACGAGAGACTC-3′ and 5′-GGAACCACCGGATCACTAAG-3′, and 5′-GTATAA-GGGAGCTTGACTG-3′ and 5′-GGGTTTCACACTTA-GATG-3′. The entire L22 (rplV) and L4 (rplD) genes were amplified, using pairs of primers 5′-GCTGACGACAAG-AAAACACG-3′ and 5′-GCCGACACGCATACCAATTG-3′, and 5′-CAAGTCAGGAGTTAAAGCTGC-3′ and 5′-CA-ACTTCGAAAGTGTATTTGCC-3′, respectively. The three amplified rrl fragments (two for domain V and one for domain II) included bases critical for erythromycin resistance (G2057, A2058, A2062, G2505, C2611, A752 and A754). Amplicons were obtained for erythromycin-susceptible and -resistant strains and were subsequently analysed by singlestrand conformation polymorphism (SSCP) as follows. Aliquots of 20 µL H 2 O containing 20 ng of PCR product were mixed with 20 µL of denaturant solution (95% formamide, 0.05% bromophenol blue, 0.05% xylene cyanol, 20 mM EDTA). The mixture was heated for 10 min at 100°C and cooled on ice, and the single-strand PCR product was then separated by non-denaturing PAGE (10% acrylamide 29-bisacrylamide 1 in Tris-borate/EDTA buffer) by using the vertical slab gel unit model SE 400 (Hoefer Scientific Instruments, San Francisco, CA, USA). The gel was run for 12-15 h at 200 V at 4°C. Bands were then visualized by ethidium bromide staining. Fragments with migration profiles differing from those of erythromycin-susceptible strains were sequenced by the dRhodamine dye terminator method with an Abi Prism 377 sequencer (Perkin-Elmer Corp., Norwalk, CT, USA). The oligonucleotides used for PCR were also used as primers for DNA sequencing.
Results
Macrolide resistance phenotypes
MICs of macrolides and related antibiotics for S. pyogenes strains are shown in Table 1 . Strain 237 was borderline susceptible to erythromycin, resistant to azithromycin and highly resistant to spiramycin (a 16-membered macrolide). The MIC of telithromycin for strain 237 was low, although it was threeto seven-fold higher than the MIC for susceptible strains. Activities of clindamycin, dalfopristin (A-type streptogramin), quinupristin (B-type streptogramin) and quinupristin-dalfopristin were similar to those against control strains. This phenotype of resistance to macrolides with susceptibility to clindamycin and streptogramins could be defined as an M phenotype. S. pyogenes 544 was resistant to azithromycin but remained susceptible to erythromycin despite a nearly five-fold increase in MIC, and to spiramycin. Again, telithromycin was active. In contrast to strain 237, S. pyogenes 544 was resistant to clindamycin and had an increased quinupristin MIC, although synergy between the two streptogramins was maintained. This phenotype could be defined as an MLS B phenotype.
Macrolide resistance genotypes
PCR experiments showed that no known acquired resistance gene could be amplified from DNA of the azithromycinresistant strains. Recent literature data has suggested that macrolide resistance could result from mutations of ribosomal structures, including domains II and V of 23S rRNA, and ribosomal proteins L4 and L22, in a variety of micro-organisms, including S. pneumoniae. [13] [14] [15] [16] [17] These ribosomal structures are involved directly or indirectly in macrolide binding. To explore this hypothesis, we carried out analysis of the DNA sequences encoding these RNA sequences or proteins. Amplicons were obtained from azithromycin-susceptible and -resistant strains and were analysed by SSCP. By this technique, a single base pair change produces a migration profile different from that visualized for the wild-type DNA. 18 We have confirmed previously the sensitivity of this technique, by the detection of a single mutation in sequences of 23S rRNA and rplD genes in mutants of S. pneumoniae. 13 Migration profiles for S. pyogenes strains showed differences in the domain V amplicon of strain 544 and in the rplD amplicon of strain 237. Sequencing of the fragments in both directions revealed a C2611U mutation in domain V of 23S rRNA in S. pyogenes 544. In S. pneumoniae containing four copies of the rrl genes, the SSCP technique allowed us to distinguish a single wild-type copy from three mutated copies, on the basis of heterogeneous electrophoretic profiles. 13 S. pyogenes has six copies of the rrl gene and the homogeneity of the electrophoretic profile of the amplicon from strain 544 indicated that all copies were mutated. 15 S. pyogenes 237 harboured an insertion of six nucleotides in the sequence of the rplD gene. This insertion would result in an insertion of the two amino acids K and G after position 69. This insertion occurred in a highly conserved fragment of the L4 protein, 63 KPWRQKGTGRAR 74 . 17
Discussion
In the two strains of azithromycin-resistant S. pyogenes studied, which lacked erm and mef(A) genes, resistance was associated with mutations of domain V of 23S rRNA at position C2611 and the L4 protein, respectively. In the absence of other mutations in the bases critical for erythromycin resistance in 23S rRNA and in the two proteins L4 and L22, the mutations identified explained macrolide resistance in our strains, which is a similar finding to that made with other bacterial species. [13] [14] [15] 17 C2611 is a residue that pairs with G2057 in the secondary structure of 23S rRNA, and the C2611U mutation results in a disruption in the rRNA structure at the end of the stem preceding the single-stranded portion of the peptidyl transferase region containing A2058 and A2059. 19 So far, the C2611U mutation has been characterized in erythromycin-resistant laboratory mutants of E. coli and a C2611A/G mutation in laboratory mutants of S. pneumoniae. [13] [14] [15] 20 In S. pneumoniae, C2611 mutations increased the MICs of 14-and 15-membered macrolides, telithromycin, lincosamides and streptogramin B. 13, 14 In S. pyogenes, this mutation yielded cross-resistance between azithromycin, clindamycin and streptogramin B (MLS B resistance). The MIC differed according to the macrolide tested. The strains were categorized as resistant to azithromycin but susceptible to erythromycin. The low MIC of telithromycin could be explained by the ability of this ketolide to bind domain II of 23S rRNA as an alternative to mutated domain V, which no longer binds macrolides. 21 Mutations in the L4 protein of S. pyogenes strains and of S. pneumoniae selected in vitro and in vivo were clustered in an identical conserved region (Figure 1 ). 14 This region is located in a segment of the L4 protein joining two α-helices, designated α3 and α2, which is essential for the binding of this protein to 23S rRNA. 22, 23 In E. coli, L4 mutations perturb the three-dimensional structure of 23S rRNA at multiple sites and, hypothetically therefore, could prevent macrolide binding by affecting the opening of the nascent peptide exit tunnel. 24, 25 In S. pyogenes, the mutation resulted in cross-resistance between the macrolides tested with elevated MICs of spiramycin. To the best of our knowledge, mutations in 23S rRNA have never been reported in clinical isolates or laboratory mutants of S. pyogenes, although a few S. pyogenes strains with L4 mutations were reported in a recent study on the efficacy of azithromycin in the treatment of pharyngitis. 26 This concomitant report of mutational resistance might indicate that this new type of resistance is emerging, or alternatively, that its prevalence has been underestimated so far. The impact of the resistance on the efficacy of therapy with macrolides, and on clinical out- 
